Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma

Ko, Hui‐Hsin; Cheng, Shih‐Jung; Lee, Jang‐Jaer; Chen, Hsin‐Ming; Kuo, Mark Yen‐Ping

doi:10.1002/hed.24759

Cited by 27 publications

(30 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we confirmed that high expression of AKR1B10 was a common feature (62%; Table ) and was a valuable prognostic marker for OSCC (Table ). Our results were consistent with the study by Ko et al in that high level of AKR1B10 expression is associated with poor prognosis in OSCC . A following study has indicated that the level of AKR1B10 in saliva could be an indicator for screening high‐risk patients and monitoring the progression of OSCC .…”

Section: Discussionsupporting

confidence: 93%

“…Our results were consistent with the study by Ko et al in that high level of AKR1B10 expression is associated with poor prognosis in OSCC. 18 A following study has indicated that the level of AKR1B10 in saliva could be an indicator for screening highrisk patients and monitoring the progression of OSCC. 21 Here, our study further demonstrated that high expression of AKR1B10 was correlated with increased incidence of tumor recurrence ( Table 2) and short disease-free survival ( Figure 2D to F).…”

Section: Discussionmentioning

confidence: 99%

“…A 2012 study of cancer gene expression database indicated that AKR1B10 is downregulated in head and neck cancer compared with normal tissues . However, a recent study by Ko et al have revealed that AKR1B10 is overexpressed and associated with poor prognosis in OSCC . Due to the discordance of these studies in AKR1B10 expression in OSCC, it is worth further investigation to clarify its role in the carcinogenesis of OSCC.…”

Section: Introductionmentioning

confidence: 99%

“…17 However, a recent study by Ko et al have revealed that AKR1B10 is overexpressed and associated with poor prognosis in OSCC. 18 Due to the discordance of these studies in AKR1B10 expression in OSCC, it is worth further investigation to clarify its role in the carcinogenesis of OSCC. Here, we studied the expression profile of AKR1B10 in a cohort of 107 OSCC patients and evaluated its correlation with the clinicopathological characteristics and the patient survival.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients

Fang

Lin

Chen

2019

J Oral Pathology Medicine

View full text Add to dashboard Cite

Background Aldo‐keto reductase family 1 member B10 (AKR1B10) is an enzyme implicated in physiological xenobiotic detoxification and also in pathological carcinogenesis. Overexpression of AKR1B10 has been reported in oral squamous cell carcinoma (OSCC), but its correlation with clinical prognosis is controversial. The aim of this study was to investigate and clarify the role of AKR1B10 in OSCC carcinogenesis. Methods Tumor tissue specimens were surgically obtained from 107 patients with OSCC. The expression of AKR1B10 was analyzed by immunohistochemistry to explore the relationship between the level of AKR1B10 and clinicopathological features of OSCC patients. Kaplan‐Meier survival and Cox proportional hazard analysis were used to determine the prognostic value of AKR1B10 in OSCC. Results High expression of AKR1B10 was found to be associated with tumor size (P = 0.043), perineural invasion (P = 0.012), and recurrence (P = 0.001) in OSCC. Cox model analysis revealed that high expression of AKR1B10 is significantly associated with poor overall and disease‐free survival in OSCC patients. With the combination of clinicopathological factors in analysis, we found that the expression level of AKR1B10 was a practical indicator that could categorize OSCC patients into different risk groups. High expression of AKR1B10 was associated with a reduced survival in patients with well and moderately differentiated OSCC and even a high incidence of tumor recurrence in the patients with late‐stage (III and IV) disease. Conclusion We validated and expanded data on the expression of AKR1B10 in OSCC, suggesting that it is a valuable biomarker for prognostic prediction of recurrence and survival in OSCC.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients

Fang

Lin

Chen

2019

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

“…[5][6][7] Elevated expression of AKR1B10 is found in nonsmall cell lung, hepatocellular, nasopharyngeal, cervical, pancreatic, and breast carcinomas. 14 AKR1B10 is a secretory protein. Recently, we demonstrated that a higher mean AKR1B10 labeling score, as assessed using immunochemical staining, is significantly associated with an advanced TNM classification and shorter survival in patients with OSCC.…”

Section: Introductionmentioning

confidence: 99%

Increased salivary AKR1B10 level: Association with progression and poor prognosis of oral squamous cell carcinoma

Peng

Cheng

et al. 2018

Head & Neck

Self Cite

View full text Add to dashboard Cite

Background Aldo‐keto reductase family 1 member B10 (AKR1B10) expression in oral squamous cell carcinoma (OSCC) tissue specimens is correlated with the progression and prognosis of OSCC. Methods Saliva samples were obtained from 35 normal controls and 86 patients with OSCC before cancer surgery. The AKR1B10 levels were determined using enzyme‐linked immunosorbent assay (ELISA). Results The mean salivary AKR1B10 levels were significantly higher in the patients with OSCC than in the normal controls (P < .001). Higher salivary AKR1B10 levels were significantly associated with larger tumor size, more advanced clinical stage, and areca quid chewing habit. Patients with OSCC with a higher salivary AKR1B10 level (>646 pg/mL) had a significantly poorer survival than those with a lower (≤646 pg/mL) salivary AKR1B10 level (P = .026). Conclusion The salivary AKR1B10 level may be a promising biomarker for screening high‐risk patients with OSCC and monitoring the progression of OSCC.

show abstract

scDiffCoAM: A complete framework to identify potential biomarkers for esophageal squamous cell carcinoma using scRNA-Seq data analysis

Saikia,

Bhattacharyya,

Kalita

2024

J Biosci

View full text Add to dashboard Cite

Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma

Abstract: AKR1B10 overexpression is an independent poor prognostic biomarker for OSCC. AKR1B10 inhibitors may be promising in clinical trials against OSCC. © 2017 Wiley Periodicals, Inc. Head Neck 39: 1327-1332, 2017.

Cited by 27 publications

References 37 publications

Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients

Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients

Increased salivary AKR1B10 level: Association with progression and poor prognosis of oral squamous cell carcinoma

scDiffCoAM: A complete framework to identify potential biomarkers for esophageal squamous cell carcinoma using scRNA-Seq data analysis

Contact Info

Product

Resources

About